At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 56 enrolled
Drug / intervention
R-(-)-gossypol acetic acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of R-(-)-Gossypol (Ascenta's AT-101) in Recurrent Glioblastoma Multiforme
In Brief
A Phase 2 clinical trial evaluating R-(-)-gossypol acetic acid and laboratory biomarker analysis for Adult Giant Cell Glioblastoma and 3 related conditions. Completed, enrolled 56 participants across 8 sites.
Detailed Summary
This phase II trial is studying how well gossypol works in treating patients with progressive or recurrent glioblastoma multiforme. Gossypol may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2007
Enrollment StartJan 2008
Primary CompletionJun 2012
TodayJul 2026
First PostedOct 8, 2007
Enrollment StartJan 1, 2008
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 18.7 years ago
Interventions
R-(-)-gossypol acetic aciddrug
Given PO
laboratory biomarker analysisother
Correlative studies